By Denny Jacob
Danaher posted improved results across key metrics in its latest quarter, which it attributed to momentum in its bioprocessing unit and demand above expectations in its molecular diagnostics business.
The manufacturing conglomerate logged earnings of $954 million, or $1.32 a share, for the first quarter ended March 28, down from $1.09 billion, or $1.45 a share, in the prior-year period.
Stripping out certain one-time items, earnings came in at $1.88 a share. Analysts polled by FactSet had expected $1.63 a share.
Sales edged down to $5.74 billion from about $5.8 billion. Analysts polled by FactSet had expected $5.57 billion.
Chief Executive Rainer Blair said revenue, earnings and cash flow exceeded expectations, thanks to continued momentum in bioprocessing and better-than-expected respiratory demand in its molecular diagnostics business. He also noted that the macroeconomic backdrop has become more dynamic since the start of the year.
For the second quarter, Danaher forecast adjusted revenue to grow by low-single digits year-over-year. The company also guided for adjusted earnings per share of between $7.60 and $7.75 for 2025, in line with analysts' estimates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 22, 2025 06:19 ET (10:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.